



## DAFTAR PUSTAKA

- Agarwal, R. (2016) ‘Defining end-stage renal disease in clinical trials: a framework for adjudication: Table 1.’, *Nephrology Dialysis Transplantation*, 31(6), pp. 864–867. Available at: <https://doi.org/10.1093/ndt/gfv289>.
- Ahmed, S. and El-Sherif, A. (2016) *Interaction between Blood and Dialysis Membrane in Hepatitis-C Virus-infected Patients: A Comparative Study*, *Saudi J Kidney Dis Transpl.* Available at: <http://www.sjkdt.org>.
- Alberti A, Benvegnu L. (2008) Hepatitis c. Dalam: Rodes J, Benhamou JP, Blei AT, Reichen J, Rizzetto M. eds. Textbook of hepatology from basic science to clinical practice. Edisi ketiga. London: Oxford. Blackwell publishing
- Ando, M. et al. (2001) ‘New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels.,’ *Blood*, 97(4), pp. 915–21. doi:10.1182/blood.v97.4.915.
- Basit, H., Tyagi, I. and Koirala, J. (2022) *Hepatitis C*.
- Batalini, F. et al. (2019) “Haemodialysis-associated thrombocytopenia: Interactions among the immune system, membranes and sterilisation methods,” *BMJ Case Reports*, 12(9). doi:10.1136/bcr-2019-229594.
- Bello, A.K. et al. (2022) “Epidemiology of haemodialysis outcomes.,” *Nature reviews. Nephrology*, 18(6), pp. 378–395. doi:10.1038/s41581-022-00542-7.
- Benjamin, O. and Lappin, S.L. (2022) *End-Stage Renal Disease*.
- Bikbov, B. et al. (2020) “Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017,” *The Lancet*, 395(10225), pp. 709–733. doi:10.1016/S0140-6736(20)30045-3.
- Boccardo, P., Remuzzi, G. and Galbusera, M. (2004) “Platelet dysfunction in renal failure,” *Seminars in Thrombosis and Hemostasis*, 30(5), pp. 579–589. doi:10.1055/s-2004-835678.
- Caragea, D.C. et al. (2018) “Hepatitis C Infection in Hemodialysis Patients.,” *Current health sciences journal*, 44(2), pp. 107–112. doi:10.12865/CHSJ.44.02.02.
- CDC. 2020. *Viral Hepatitis*. [online] Available at: <<https://www.cdc.gov/hepatitis/hcv/cfaq.htm#:~:text=Hepatitis%20C%20is%20often%20described,infection%20leads%20to%20chronic%20infection>> [Accessed 5 November 2021].



- CDC. 2021. *Chronic Kidney Disease in the United States, 2021.* [online] Available at: <[https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html#:~:text=CKD%20is%20more%20common%20in,Hispanic%20Asian%20adults%20\(13%25\).](https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html#:~:text=CKD%20is%20more%20common%20in,Hispanic%20Asian%20adults%20(13%25).)> [Accessed 5 November 2021].
- CDC. 2022. *Chronic Kidney Disease Basics.* [online] Available at: <<https://www.cdc.gov/kidneydisease/basics.html>> [Accessed 5 November 2021].
- Chanpong, G.F. et al. (2002) ‘Hepatitis C among child transfusion and adult renal dialysis patients in Indonesia.’, *The American journal of tropical medicine and hygiene*, 66(3), pp. 317–20. Available at: <https://doi.org/10.4269/ajtmh.2002.66.3.17>.
- Chantrel, F. et al. (2013) “[Survival and mortality in ESRD patients],,” *Nephrologie & thérapeutique*, 9 Suppl 1, pp. S127-37. doi:10.1016/S1769-7255(13)70042-7.
- Chen, C.-B. et al. (2008) “Chronic Hepatitis C Infection Is Associated with Higher Hemoglobin Levels in Hemodialysis Patients, But Hepatitis B Infection Is Not,” *Dialysis & Transplantation*, 37(1), pp. 12–17. doi:10.1002/dat.20173.
- Chen, T.K., Knicely, D.H. and Grams, M.E. (2019) “Chronic Kidney Disease Diagnosis and Management: A Review.,,” *JAMA*, 322(13), pp. 1294–1304. doi:10.1001/jama.2019.14745.
- Chen, Y.-C. et al. (2022) ‘Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals’, *Viruses*, 14(2), p. 333. Available at: <https://doi.org/10.3390/v14020333>.
- Chikotas, N., Gunderman, A. and Oman, T. (2006) “Uremic syndrome and end-stage renal disease: Physical manifestations and beyond,” *Journal of the American Academy of Nurse Practitioners*, 18(5), pp. 195–202. doi:10.1111/j.1745-7599.2006.00123.x.
- Dahal, S. et al. (2017) “Thrombocytopenia in patients with chronic hepatitis C virus infection,” *Mediterranean Journal of Hematology and Infectious Diseases*, 9(1). doi:10.4084/mjhid.2017.019.
- Daugirdas, J.T. and Bernardo, A.A. (2012) ‘Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia’, *Kidney International*, 82(2), pp. 147–157. Available at: <https://doi.org/10.1038/ki.2012.130>.



- Diaz-Ricart, M. (2005) *Uremic platelet dysfunction Cardiovascular risk in CKD View project Functionalized CoCr alloy surfaces with cell adhesive molecules to improve endothelialization View project Ginés Escolar Hospital Clinic de Barcelona.* Available at: <https://www.researchgate.net/publication/7630382>.
- Eknayan, G. (2013) ‘KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease’, *International Society of Nephrology*, 3(1).
- Elsharif, M.E. (2011) “Mortality rate of patients with end stage renal disease on regular hemodialysis: a single center study.,” *Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia*, 22(3), pp. 594–6.
- Etik, D.O., Ocal, S. and Boyacioglu, A.S. (2015) “Hepatitis C infection in hemodialysis patients: A review,” *World Journal of Hepatology*, 7(6), pp. 885–895. doi:10.4254/wjh.v7.i6.885.
- Escolar, G., Díaz-Ricart, M. and Cases, A. (2005) ‘Uremic platelet dysfunction: past and present.’, *Current hematology reports*, 4(5), pp. 359–67.
- Fouad, Y.M. (2013) “Chronic hepatitis C-associated thrombocytopenia: aetiology and management,” *Tropical Gastroenterology*, 34(2), pp. 58–67. doi:10.7869/tg.2012.99.
- Fountain, J.H. and Lappin, S.L. (2022) *Physiology, Platelet*.
- Fritiwi, D.H. et al. (2019) ‘HIGHER D-DIMER VALUE IN PATIENTS RECEIVING CONTINUOUS HEPARIN COMPARED TO INTERMITTENT HEPARIN DURING REGULAR HAEMODIALYSIS’, *INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY*, 25(3), p. 307. Available at: <https://doi.org/10.24293/ijcpml.v25i3.1461>.
- Furusyo, N. (2000) ‘Liver Damage in Hemodialysis Patients with Hepatitis C Virus Viremia: A Prospective 10-Year Study’, *Digestive Diseases and Sciences*, 45(11), pp. 2221–2228. Available at: <https://doi.org/10.1023/A:1026696721059>.
- Gafter, U. et al. (1987) “Platelet Count and Thrombopoietic Activity in Patients with Chronic Renal Failure,” *Nephron*, 45(3), pp. 207–210. doi:10.1159/000184118.



- Gani (2014). Hepatitis C. Dalam : Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF (eds). Buku ajar ilmu penyakit dalam jilid 1. Edisi ke 6. Jakarta: Interna Publishing
- García, G.G. et al. (2022) ‘Sex and gender differences in chronic kidney disease and access to care around the globe’, *Seminars in Nephrology*, 42(2), pp. 101–113. Available at: <https://doi.org/10.1016/j.semephrol.2022.04.001>.
- Ghoshal, K. and Bhattacharyya, M. (2014) “Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis.”, *TheScientificWorldJournal*, 2014, p. 781857. doi:10.1155/2014/781857.
- Giannini, E. et al. (2003) ‘Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection’, *The American Journal of Gastroenterology*, 98(11), pp. 2516–2520. Available at: <https://doi.org/10.1111/j.1572-0241.2003.08665.x>.
- Guo, Q. et al. (2020) “How Can I Manage Thrombocytopenia in Hemodialysis Patient? A Review,” *Therapeutic Apheresis and Dialysis*. Blackwell Publishing Ltd, pp. 352–360. doi:10.1111/1744-9987.13448.
- del Giorno, R. et al. (2017) ‘Comparative analysis of the long-term effect of two families of high-flux polysulfone dialysers on platelet count: a retrospective cross-sectional study’, *Therapeutics and Clinical Risk Management*, Volume 13, pp. 1415–1422. Available at: <https://doi.org/10.2147/TCRM.S143708>.
- Halle, M.P. et al. (2015) ‘Epidemiological profile of patients with end stage renal disease in a referral hospital in Cameroon’, *BMC Nephrology*, 16(1), p. 59. Available at: <https://doi.org/10.1186/s12882-015-0044-2>.
- Harris, R.C. and Zhang, M.-Z. (2020) ‘The role of gender disparities in kidney injury.’, *Annals of translational medicine*, 8(7), p. 514. Available at: <https://doi.org/10.21037/atm.2020.01.23>.
- Hartsock, R.J., Smith, E.B. and Petty, C.S. (1965) ‘Normal Variations with Aging of the Amount of Hematopoietic Tissue in Bone Marrow from the Anterior Iliac Crest: A Study Made from 177 Cases of Sudden Death Examined by Necropsy’, *American Journal of Clinical Pathology*, 43(4), pp. 326–331. Available at: <https://doi.org/10.1093/ajcp/43.4.326>.
- Hecking, M. et al. (2014) ‘Sex-specific differences in hemodialysis prevalence and practices and the male-to-female mortality rate: the Dialysis Outcomes and Practice Patterns Study (DOPPS).’, *PLoS medicine*, 11(10), p. e1001750. Available at: <https://doi.org/10.1371/journal.pmed.1001750>.



- Hofbauer, R. *et al.* (1999) ‘Effect of anticoagulation on blood membrane interactions during hemodialysis’, *Kidney International*, 56(4), pp. 1578–1583. Available at: <https://doi.org/10.1046/j.1523-1755.1999.00671.x>.
- Hoffbrand, A.V., Petit, J.E., Moss, P. A. H., (2005). *Kapita Selekta Hematologi*. Edisi 4. Jakarta: Penerbit Buku Kedokteran EGC.
- Holinstat, M. (2017) “Normal platelet function.,” *Cancer metastasis reviews*, 36(2), pp. 195–198. doi:10.1007/s10555-017-9677-x.
- Honma, Y. *et al.* (2019) “Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease.,” *Liver international: official journal of the International Association for the Study of the Liver*, 39(9), pp. 1641–1651. doi:10.1111/liv.14120.
- Huang, C.-E. *et al.* (2021) “Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infection,” *Biomedical Journal* [Preprint]. doi:10.1016/J.BJ.2021.09.001.
- Hytiroglou, P. (2011) ‘Hepatitis C’, in *Practical Hepatic Pathology: A Diagnostic Approach*. Elsevier, pp. 225–233. Available at: <https://doi.org/10.1016/B978-0-443-06803-4.00018-6>.
- Ikarashi, Y. *et al.* (2018) ‘The Clinical Difference in the Platelet Counts between Liver Cirrhosis with Nonalcoholic Fatty Liver Disease and Hepatitis C Virus’, *Internal Medicine*, 57(8), pp. 1065–1070. Available at: <https://doi.org/10.2169/internalmedicine.9853-17>.
- Irshad, M., Mankotia, D.S. and Irshad, K. (2013) “An insight into the diagnosis and pathogenesis of hepatitis C virus infection.,” *World journal of gastroenterology*, 19(44), pp. 7896–909. doi:10.3748/wjg.v19.i44.7896.
- Jacobson, I.M. *et al.* (2010) “Manifestations of Chronic Hepatitis C Virus Infection Beyond the Liver,” *Clinical Gastroenterology and Hepatology*, pp. 1017–1029. doi:10.1016/j.cgh.2010.08.026.
- Jameson, J.L. and Loscalzo, J. (2013) Harrison’s Nephrology and Acid-Base Disorders. 2nd edn. Edited by D.L. Longo et al. Pennsylvania: McGraw-Hill Education.
- Jannah, N. *et al.* (2021) “HUBUNGAN FREKUENSI LAMA MENJALANKAN HD DENGAN KADAR TROMBOSIT PADA PASIEN CKD DI RSPBA BANDAR LAMPUNG,” *Jurnal Medika Malahayati*, 5(3), pp. 170–175.
- Jinna, S. and Khandhar, P.B. (2022) *Thrombocytopenia*.



- Jones, C.I. (2016) ‘Platelet function and ageing’, *Mammalian Genome*, 27(7–8), pp. 358–366. Available at: <https://doi.org/10.1007/s00335-016-9629-8>.
- Kahdina, M., Mardiana, N. and Fauziah, D. (2018) ‘Levels of Hemoglobin, Leukocytes, and Platelets of Chronic Kidney Disease Patients Undergoing Hemodialysis in Surabaya’, *Biomolecular and Health Science Journal* [Preprint].
- Kandacong, A.C. (2017) *JUMLAH TROMBOSIT PRE DAN POST HEMODIALISIS (HD) PADA PASIEN PENYAKIT GAGAL GINJAL KRONIK (PGK) DI RUMAH SAKIT PERGURUAN TINGGI NEGERI (RSPTN) UNIVERSITAS HASANUDDIN*. UNIVERSITAS HASANUDDIN.
- Kato, A. et al. (2003) ‘Elevation of blood thioredoxin in hemodialysis patients with hepatitis C virus infection’, *Kidney International*, 63(6), pp. 2262–2268. Available at: <https://doi.org/10.1046/j.1523-1755.2003.t01-3-00002.x>.
- Kurokawa, T. and Ohkohchi, N. (2017) “Platelets in liver disease, cancer and regeneration,” *World Journal of Gastroenterology*, 23(18), pp. 3228–3239. doi:10.3748/wjg.v23.i18.3228.
- Lambert, M.P. (2016) “Platelets in liver and renal disease,” *Hematology*, 2016(1), pp. 251–255. doi:10.1182/asheducation-2016.1.251.
- Lazrak, H.H. et al. (2017) ‘Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis.’, *BMC nephrology*, 18(1), p. 187. Available at: <https://doi.org/10.1186/s12882-017-0596-4>.
- Li, H.-C. and Lo, S.-Y. (2015) “Hepatitis C virus: Virology, diagnosis and treatment.”, *World journal of hepatology*, 7(10), pp. 1377–89. doi:10.4254/wjh.v7.i10.1377.
- Lv, J.-C. and Zhang, L.-X. (2019) ‘Prevalence and Disease Burden of Chronic Kidney Disease.,’ *Advances in experimental medicine and biology*, 1165, pp. 3–15. doi:10.1007/978-981-13-8871-2\_1.
- Lydia, A. et al. (2019) ‘Liver fibrosis of hepatitis C virus infection in routine hemodialysis patients in Indonesia’, *Medical Journal of Indonesia*, 28(4), pp. 375–9. Available at: <https://doi.org/10.13181/mji.v28i4.3776>.
- Mackenzie, T.A., Zawada, E.T. and Stacy, W.K. (1985) “Hemodialysis,” *Postgraduate Medicine*, 77(1), pp. 95–104. doi:10.1080/00325481.1985.11698842.



- Man, N.K., Zingraff, J. and Jungers, P. (1995) "Basic Principles of Hemodialysis," in *Long-Term Hemodialysis*. Dordrecht: Springer Netherlands, pp. 11–21. doi:10.1007/978-94-011-0027-4\_2.
- Manns, M.P. et al. (2017) "Hepatitis C virus infection," *Nature reviews. Disease primers*, 3, p. 17006. doi:10.1038/nrdp.2017.6.
- Marinaki, S. et al. (2015) 'Hepatitis C in hemodialysis patients.', *World journal of hepatology*, 7(3), pp. 548–58. Available at: <https://doi.org/10.4254/wjh.v7.i3.548>.
- Mihăilă, R.-G. (2017) *A LOOK AT PLATELET COUNT IN CHRONIC HEPATITIS C INFECTION*, Citation: *EMJ Hepatol.*
- Mohamed, S.F. (2013) "Prevalence of thrombocytopenia in Egyptian patients with chronic hepatitis C virus," *Journal of the Egyptian Society of Parasitology*, 43(3), pp. 617–628. doi:10.12816/0006419.
- Murdeswar, H.N. and Anjum, F. (2022) *Hemodialysis*.
- Ng, Y.-Y. et al. (2002) "Leukopenia and thrombocytopenia in hemodialysis patients with hepatitis B or C virus infection and non-hemodialysis patients with hepatitis cirrhosis," *Clinical Nephrology*, 57(04), pp. 289–295. doi:10.5414/CNP57289.
- Noguchi, H. et al. (1995) 'Changes in platelet kinetics after a partial splenic arterial embolization in cirrhotic patients with hypersplenism.', *Hepatology (Baltimore, Md.)*, 22(6), pp. 1682–8.
- Nugent, R.A. et al. (2011) "The Burden of Chronic Kidney Disease on Developing Nations: A 21st Century Challenge in Global Health," *Nephron Clinical Practice*, 118(3), pp. c269–c277. doi:10.1159/000321382.
- Olariu, M., Olariu, C. and Olteanu, D. (2010) 'Thrombocytopenia in chronic hepatitis C.', *Journal of gastrointestinal and liver diseases : JGLD*, 19(4), pp. 381–5.
- Orasan, O. et al. (2018) "Thrombocytopenia in end-stage renal disease and chronic viral hepatitis B or C," *Journal of Mind and Medical Sciences*, 5(2), pp. 236–243. doi:10.22543/7674.52.p236243.
- Patel, S.R., Hartwig, J.H. and Italiano, J.E. (2005) "The biogenesis of platelets from megakaryocyte proplatelets," *The Journal of clinical investigation*, 115(12), pp. 3348–54. doi:10.1172/JCI26891.
- Poppelaars, F. et al. (2018) "The Complement System in Dialysis: A Forgotten Story?," *Frontiers in immunology*, 9, p. 71. doi:10.3389/fimmu.2018.00071.



- Radkowski, M. *et al.* (2000) “Detection of active hepatitis C virus and hepatitis G virus/GB virus C replication in bone marrow in human subjects.” *Blood*, 95(12), pp. 3986–9.
- Rods, J. *et al.* (eds) (2007) *Textbook of Hepatology*. Oxford, UK: Blackwell Publishing Ltd. doi:10.1002/9780470691861.
- Reid, M., Price, J.C. and Tien, P.C. (2017) ‘Hepatitis C Virus Infection in the Older Patient’, *Infectious Disease Clinics of North America*, 31(4), pp. 827–838. Available at: <https://doi.org/10.1016/j.idc.2017.07.014>.
- SANJO, A. *et al.* (2003) ‘Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases’, *Journal of Gastroenterology and Hepatology*, 18(6), pp. 638–644. Available at: <https://doi.org/10.1046/j.1440-1746.2003.03026.x>.
- Schlappi, C. et al. (2018) “Outcomes in Mild to Moderate Isolated Thrombocytopenia.” *Pediatrics*, 142(1). doi:10.1542/peds.2017-3804.
- Segal, J.B. and Moliterno, A.R. (2006) ‘Platelet Counts Differ by Sex, Ethnicity, and Age in the United States’, *Annals of Epidemiology*, 16(2), pp. 123–130. Available at: <https://doi.org/10.1016/j.annepidem.2005.06.052>.
- Shah, R. *et al.* (2014) “Thrombocytopenia in ESRD Patients: Epidemiology, Mechanisms and Interventional Nephrology Perspective,” *Seminars in Dialysis*, 27(6), pp. 618–625. doi:10.1111/sdi.12199.
- Shao, L.-N. *et al.* (2020) ‘Platelet indices significantly correlate with liver fibrosis in HCV-infected patients’, *PLOS ONE*, 15(1), p. e0227544. Available at: <https://doi.org/10.1371/journal.pone.0227544>.
- Suhardjono (2014). Hemodialisis: Prinsip dasar dan pemakaian kliniknya. Dalam: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF (eds). Buku ajar ilmu penyakit dalam jilid 1. Edisi ke 6. Jakarta: Interna Publishing
- Sun, J. et al. (2009) ‘Hepatitis C Infection and Related Factors in Hemodialysis Patients in China: Systematic Review and Meta-Analysis’, *Renal Failure*, 31(7), pp. 610–620. Available at: <https://doi.org/10.1080/08860220903003446>.
- Stenvinkel, P. (2006) “Inflammation in end-stage renal disease: the hidden enemy.” *Nephrology (Carlton, Vic.)*, 11(1), pp. 36–41. doi:10.1111/j.1440-1797.2006.00541.x.
- Wang, C.-S. *et al.* (2004) *Strong Association of Hepatitis C Virus (HCV) Infection and Thrombocytopenia: Implications from a Survey of a Community with*



*Hyperendemic HCV Infection.* Available at:  
<https://academic.oup.com/cid/article/39/6/790/357870>.

WEKSLER, B.B. (2007) “Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease,” *Alimentary Pharmacology & Therapeutics*, 26, pp. 13–19. doi:10.1111/j.1365-2036.2007.03512.x.

Welenga, J.M. et al. (2004) ‘Decreased Prevalence of Heparin-Induced Thrombocytopenia with Low-Molecular-Weight Heparin and Related Drugs’, *Seminars in Thrombosis and Hemostasis*, 30, pp. 69–80. Available at: <https://doi.org/10.1055/s-2004-823005>.

Westbrook, R.H. and Dusheiko, G. (2014) “Natural history of hepatitis C,” *Journal of hepatology*, 61(1 Suppl), pp. S58-68. doi:10.1016/j.jhep.2014.07.012.

Whittier, W.L. and Lewis, E.J. (2014) “Pathophysiology of Chronic Kidney Disease,” in *National Kidney Foundation Primer on Kidney Diseases*. Elsevier, pp. 448–457. doi:10.1016/B978-1-4557-4617-0.00052-2.

Wyles, D. and Lin, J. (no date) *Clinical Manifestations of Acute and Chronic Hepatitis SECTION 2 Syndromes by Body System: The Gastrointestinal System*.